Skip to main content
Midas Edge

IONIS PHARMACEUTICALS INC

For the period ended Jun 30, 2025. Filed Jul 30, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Jul 30, 2025

IONS$28.19-9.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statements of Stockholders’ Equity

Common Stock · Additional · Accumulated Other · Total
DescriptionSharesAmountPaid in CapitalComprehensive LossAccumulated DeficitStockholders' Equity
Balance at March 31, 2024145,845$146$2,270,047$(34,964)$(1,938,714)$296,515
Net loss----(66,265)(66,265)
Change in unrealized gains, net of tax---150-150
Foreign currency translation---(24)-(24)
Issuance of common stock in connection with employee stock plans, net180-2,594--2,594
Stock-based compensation expense--30,728--30,728
Balance at June 30, 2024146,025$146$2,303,369$(34,838)$(2,004,979)$263,698
Balance at March 31, 2025159,041$159$2,901,262$(28,949)$(2,396,746)$475,726
Net income----123,551123,551
Change in unrealized gains, net of tax---367-367
Foreign currency translation---595-595
Issuance of common stock in connection with employee stock plans, net156-1,286--1,286
Stock-based compensation expense--30,199--30,199
Balance at June 30, 2025159,197$159$2,932,747$(27,987)$(2,273,195)$631,724

Index

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

Common Stock · Additional · Accumulated Other · Total
DescriptionSharesAmountPaid in CapitalComprehensive LossAccumulated DeficitStockholders' Equity
Balance at December 31, 2023144,341$144$2,215,098$(32,645)$(1,795,911)$386,686
Net loss----(209,068)(209,068)
Change in unrealized losses, net of tax---(2,056)-(2,056)
Foreign currency translation---(137)-(137)
Issuance of common stock in connection with employee stock plans, net1,684226,203--26,205
Stock-based compensation expense--62,068--62,068
Balance at June 30, 2024146,025$146$2,303,369$(34,838)$(2,004,979)$263,698
Balance at December 31, 2024157,909$158$2,868,812$(30,811)$(2,249,808)$588,351
Net loss----(23,387)(23,387)
Change in unrealized gains, net of tax---1,997-1,997
Foreign currency translation---827-827
Issuance of common stock in connection with employee stock plans, net1,28813,527--3,528
Stock-based compensation expense--60,408--60,408
Balance at June 30, 2025159,197$159$2,932,747$(27,987)$(2,273,195)$631,724

Index

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.